Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

Autor: Caroline Bascoul-Mollevi, Alexandre Ho-Pun-Cheung, Bruno Robert, Frédérique Penault-Llorca, Christelle Larbouret, Isabelle Navarro-Teulon, Jean-Pierre Mach, David Azria, André Pèlegrin, Sébastien Morisseau

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2010, 21 (1), pp.98-103. ⟨10.1093/annonc/mdp496⟩
Annals of Oncology, vol. 21, no. 1, pp. 98-103

International audience; BACKGROUND: Pancreatic carcinoma remains a treatment-refractory cancer with a poor prognosis. Here, we compared anti-epidermal growth factor receptor (EGFR) and anti-HER2 monoclonal antibodies (2mAbs) injections with standard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9496c139250ed8d2aa60fdcb91f9bdb
http://doc.rero.ch/record/302737/files/mdp496.pdf